ACADIA Pharmaceuticals Inc. vs Build A Bear Workshop Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Build A Bear Workshop Inc trades at $36.88 (market cap $467.15M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 10.8× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.47% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BBW | |
|---|---|---|
Market Cap | $5.06B | $467.15M |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $75.85 |
52-Week Low | $20.06 | $29.84 |
Enterprise Value | $4.18B | $566.59M |
Dividend Yield | — | 2.47% |
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
Build-A-Bear Workshop (BBW) trades at $36.86, up 6.19% today, with a bullish technical signal and strong analyst support. The stock exhibits attractive valuation metrics, including a P/E of 8.73 and P/S of 0.92, alongside robust profitability with a 10.48% net income margin and 35.87% ROE. Recent earnings have consistently beaten estimates, and the company maintains a debt-free balance sheet while executing a growth strategy focused on international expansion and brand partnerships.
The outlook for BBW is positive, driven by earnings momentum and a consensus price target of $62.50 implying significant upside. Key risks include near-term consumer spending volatility and execution of expansion plans, but strong fundamentals and shareholder returns via dividends support a favorable risk-reward profile for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →